Get the Daily Brief
Latest Biotech News
First weekly HIV pill moves closer after phase 3 wins
Merck and Gilead reported positive phase 3 results for a weekly oral HIV regimen combining islatravir and lenacapavir, with both studies meeting their primary efficacy endpoints. The companies...
Biopharma record-setting IPO backs next oncology wave
Parabilis pursued a potentially record-setting Nasdaq debut, launching an IPO valued at about $670 million and earmarking proceeds to fund a cancer drug program. The company’s move comes amid...
Incyte pushes deeper into hematology with Vega’s Phase 3 VWD asset
Incyte agreed to acquire Vega Therapeutics for up to $2 billion, aiming to extend its hematology growth engine with a Phase 3 von Willebrand disease (VWD) candidate. Vega’s VGA039 is positioned as...
J&J enters degrader antibody conjugates with Firefly Bio
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, targeting a new therapeutic modality in degraders delivered via antibody conjugates. The acquisition is designed to broaden...
Gilead’s Trodelvy hits a first-line NSCLC wall
Gilead and Merck said they will stop a Phase 3 trial of Trodelvy (sacituzumab govitecan) plus Keytruda in first-line PD-L1-high non-small cell lung cancer after an external data monitoring...
Regulatory momentum in AI-enabled diagnostics and liquid biopsy
Cancer Research UK, Royal Marsden and Guardant Health partnered to expand access to ctDNA testing across the UK’s Experimental Cancer Medicine Centre (ECMC) network. CRUK said it aims to make...
Modernizing clinical trial diagnostics infrastructure via platform acquisitions
10x Genomics expanded its proteomics capabilities through the acquisition of Proteintech Genomics, aiming to integrate transcriptomic and proteomic measurements across its single-cell and spatial...
Treeline’s move to public markets via reverse merger
Treeline Biosciences outlined plans to go public through a reverse merger with Standard BioTools, with the combined company expected to trade on Nasdaq under the Treeline Biosciences name. The...
AI transforms antibody design with multi-objective learning
Researchers reported progress in multi-objective antibody design using machine learning, aiming to optimize multiple functional attributes simultaneously rather than sequentially tuning single...
GSK expands lung cancer franchise via Nuvalent acquisition
GSK agreed to acquire Nuvalent for $10.6 billion in cash, positioning the deal to add two near-commercial non-small cell lung cancer (NSCLC) programs to its pipeline. The acquisition brings...
Incyte targets von Willebrand disease with $2B Vega buy
Incyte agreed to acquire Vega Therapeutics in a deal valued at up to $2 billion to add VGA039, a Phase III candidate for von Willebrand disease (VWD). The asset is designed as a subcutaneous...
Merck and Gilead pursue first weekly oral HIV pill
Merck and Gilead reported positive results from two Phase 3 trials of a combination regimen intended to become the first weekly oral HIV treatment. The approach pairs Merck’s islatravir with...
J&J moves into degrader-antibody conjugates via Firefly Bio
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, stepping further into the emerging degrader-antibody conjugate (DAC) space. J&J said the deal expands its cancer technology...
Roche pays to co-develop Nurix BTK degrader
Roche agreed to pay Nurix Therapeutics $700 million upfront to co-develop and co-commercialize its BTK degrader bexobrutideg. The arrangement, valued at up to $2.3 billion in milestones, is...
Treeline lines up Nasdaq debut via reverse merger
Treeline Biosciences announced plans to enter public markets via a reverse merger with Standard BioTools, with the combined company expected to trade on the Nasdaq under the ticker symbol TRLN....
Dual Lassa-rabies vaccine posts Phase 1 immune and safety readouts
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported interim Phase 1 results for a dual Lassa fever–rabies vaccine in Nature...
Diagnostics expansion: Cancer Research UK, Royal Marsden, Guardant to scale ctDNA testing
Cancer Research UK, the Royal Marsden NHS Foundation Trust, and Guardant Health said they will make circulating tumor DNA (ctDNA) testing freely available for hundreds of patients with advanced...
Cell therapy and gene therapy manufacturing: VIVEbiotech adds 15th in vivo lentiviral program
VIVEbiotech reported it added its 15th in vivo lentiviral vector-based therapeutic program to its CGT platform, spanning applications such as in vivo CAR T, rare diseases, gene editing, and...
Clinical trial technology: AI precision improves liquid biopsy mutation calling
Johns Hopkins Kimmel Cancer Center researchers introduced plasmaCHORD, a machine learning approach intended to improve mutation identification accuracy from liquid biopsy samples. The tool is...
Oncology M&A: GSK lands late-stage lung assets from Nuvalent
GlaxoSmithKline agreed to buy Nuvalent for $10.6 billion, giving the UK drugmaker two late-stage, FDA-reviewed lung cancer inhibitors—zidesamtinib (NVL-520) and neladalkib (NVL-655)—with target...